Fennec Pharmaceuticals (FENC) CFO exercises 10,000 stock options at $2.45

Rhea-AI Filing Summary

Fennec Pharmaceuticals Inc. chief financial officer exercises stock options for 10,000 shares. On January 23, 2026, CFO Robert Andrade exercised stock options with a strike price of $2.45 per share, acquiring 10,000 common shares of Fennec Pharmaceuticals Inc. following an option contract that was scheduled to expire on July 5, 2026.

After this transaction, Andrade directly held 211,100 common shares of Fennec and still held 816,567 stock options with an exercise price of $2.45, according to the filing.

Insider Trade Summary

10,000 shares exercised/converted

Mixed 2 txns

Insider Andrade Robert

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Stock Options	10,000	$2.45	$25K
Exercise	Common shares	10,000	$2.45	$25K

Holdings After Transaction: Stock Options — 816,567 shares (Direct); Common shares — 211,100 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Robert

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NC 27709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	01/23/2026		M		10,000	A	$2.45	211,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options(1)	$2.45	01/23/2026		M			10,000	07/05/2016	07/05/2026	Options	10,000	$2.45	816,567	D

Explanation of Responses:

1. Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026.

	/s/ Robert Andrade	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) report for January 23, 2026?

On January 23, 2026, Fennec Pharmaceuticals reported that its chief financial officer, Robert Andrade, exercised stock options and acquired 10,000 common shares at an exercise price of $2.45 per share.

Who is the insider involved in this Fennec Pharmaceuticals (FENC) Form 4 filing?

The insider is Robert Andrade, the chief financial officer of Fennec Pharmaceuticals Inc., as identified in the Form 4 filing.

How many Fennec Pharmaceuticals (FENC) shares does the CFO own after this transaction?

Following the option exercise, CFO Robert Andrade directly owned 211,100 common shares of Fennec Pharmaceuticals Inc., according to the Form 4.

What stock options did the Fennec Pharmaceuticals (FENC) CFO exercise?

He exercised stock options with a strike price of $2.45 per share, covering 10,000 underlying common shares, from an option contract originally expiring on July 5, 2026.

How many Fennec Pharmaceuticals (FENC) stock options remain held by the CFO after this Form 4 transaction?

After the reported transaction, CFO Robert Andrade held 816,567 stock options with an exercise price of $2.45 per share, as disclosed in the filing.

Is the Fennec Pharmaceuticals (FENC) Form 4 transaction direct or indirect ownership?

The Form 4 indicates direct ownership (D) for both the common shares acquired and the stock options held by CFO Robert Andrade, with no separate entity listed for indirect ownership.